BBNX logo

Beta Bionics Inc. (BBNX)

$14.72

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BBNX

Market cap

$800283226

EPS

-1.7

P/E ratio

--

Price to sales

7.8

Dividend yield

--

Beta

3.431469

Price on BBNX

Previous close

$15.21

Today's open

$15.19

Day's range

$14.55 - $15.91

52 week range

$8.80 - $32.71

Profile about BBNX

CEO

Sean Saint

Employees

420

Headquarters

Irvine, CA

Exchange

NASDAQ Global Market

Shares outstanding

54367067

Issue type

Common Stock

BBNX industries and sectors

Healthcare

Medical Equipment & Supplies

News on BBNX

BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas

Beta Bionics launches iLet Bionic Pancreas integration with Eversense 365, offering more CGM options and boosting growth prospects in the diabetes care market.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration

Eversense 365 now works with iLet, combining a year of accurate glucose monitoring with fully adaptive, automated insulin delivery to reduce the demands of managing diabetes

news source

GlobeNewsWire • Nov 16, 2026

news preview

Beta Bionics, Inc. (NASDAQ:BBNX) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Beta Bionics, Inc. Securities Lawsuit - Contact Portnoy Law Firm

LOS ANGELES, Nov. 03, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm notifies investors in Beta Bionics, Inc. (NASDAQ: BBNX) that a securities class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the 'Class Period'). Find out if you qualify to recover your per-share losses by choosing to join the class action and submit your trade details.

news source

GlobeNewsWire • Nov 3, 2026

news preview

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Beta Bionics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBNX

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

news source

GlobeNewsWire • Nov 3, 2026

news preview

BBNX Deadline: BBNX Investors Have Opportunity to Lead Beta Bionics, Inc. Securities Fraud Lawsuit

NEW YORK, Nov. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026, both dates inclusive (the "Class Period"), of the important November 3, 2026 lead plaintiff deadline. So what: If you purchased Beta Bionics common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

news source

PRNewsWire • Nov 3, 2026

news preview

SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of November 3, 2026 in Beta Bionics, Inc. Lawsuit - BBNX

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Beta Bionics, Inc. (NASDAQ: BBNX) securities that a securities class action has been filed on behalf of shareholders who acquired shares between July 30, 2025 and February 24, 2026. Find out if you might qualify for recovery.

news source

GlobeNewsWire • Nov 3, 2026

news preview

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Beta Bionics (NASDAQ: BBNX) Investors of Securities Class Action Lawsuit Deadline on November 3, 2026

NEW YORK--(BUSINESS WIRE)---- $BBNX #BBNX--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and reminds investors of the November 3, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Th.

news source

Business Wire • Nov 3, 2026

news preview

BBNX Deadline Today: Rosen Law Firm Urges Beta Bionics, Inc. (NASDAQ: BBNX) Stockholders to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors about a class action on behalf of purchasers of common stock of Beta Bionics, Inc. (NASDAQ: BBNX) between July 30, 2025 and February 24, 2026. Beta Bionics describes itself as a “commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes.”For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Al.

news source

Business Wire • Nov 3, 2026

news preview

Beta Bionics Announces Participation at Upcoming Investor Conferences

IRVINE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will participate at upcoming investor conferences: Members of the Company's management team will present at the Wolfe Research 8th Annual Healthcare Conference on Tuesday, November 10, 2026 at 12:40pm Eastern Time.

news source

GlobeNewsWire • Nov 3, 2026

news preview

BBNX Investor Alert: Schall, Brown & Schwartz LLP Files Class Action Lawsuit Against Beta Bionics, Inc. and Announces Opportunity for Investors to Lead Class Action Lawsuit

LOS ANGELES, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, announces that it has filed a federal securities class action on behalf of purchasers of Beta Bionics, Inc. (“Beta Bionics” or “the Company”) (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). Beta Bionics investors have until November 3, 2026 to seek appointment as lead plaintiff of the purported class in the Beta Bionics class action lawsuit.

news source

GlobeNewsWire • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Beta Bionics Inc.

Open an M1 investment account to buy and sell Beta Bionics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BBNX on M1